CA2369183A1 - Moyens et methodes pour evaluer un traitement - Google Patents
Moyens et methodes pour evaluer un traitement Download PDFInfo
- Publication number
- CA2369183A1 CA2369183A1 CA002369183A CA2369183A CA2369183A1 CA 2369183 A1 CA2369183 A1 CA 2369183A1 CA 002369183 A CA002369183 A CA 002369183A CA 2369183 A CA2369183 A CA 2369183A CA 2369183 A1 CA2369183 A1 CA 2369183A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- seq
- nucleic acid
- type
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 81
- 238000011282 treatment Methods 0.000 title claims abstract description 66
- 238000011156 evaluation Methods 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 137
- 230000014509 gene expression Effects 0.000 claims abstract description 99
- 239000003550 marker Substances 0.000 claims abstract description 66
- 210000004027 cell Anatomy 0.000 claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 37
- 230000033115 angiogenesis Effects 0.000 claims abstract description 34
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 34
- 210000004369 blood Anatomy 0.000 claims abstract description 26
- 239000008280 blood Substances 0.000 claims abstract description 26
- 208000007766 Kaposi sarcoma Diseases 0.000 claims abstract description 15
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 14
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 11
- 230000000977 initiatory effect Effects 0.000 claims abstract description 10
- 230000015556 catabolic process Effects 0.000 claims abstract description 4
- 238000012423 maintenance Methods 0.000 claims abstract description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 179
- 108020004707 nucleic acids Proteins 0.000 claims description 178
- 102000039446 nucleic acids Human genes 0.000 claims description 178
- 108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 claims description 25
- 238000001514 detection method Methods 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 claims description 14
- 108010066321 Keratin-14 Proteins 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 238000009007 Diagnostic Kit Methods 0.000 claims description 9
- 230000002491 angiogenic effect Effects 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000002405 diagnostic procedure Methods 0.000 claims description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 3
- 210000004524 haematopoietic cell Anatomy 0.000 claims description 3
- 229950003608 prinomastat Drugs 0.000 claims description 3
- YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 claims description 3
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 3
- 229960005314 suramin Drugs 0.000 claims description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 claims description 2
- 108010079505 Endostatins Proteins 0.000 claims description 2
- 102000006992 Interferon-alpha Human genes 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 108010016076 Octreotide Proteins 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 claims description 2
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 claims description 2
- 229950010817 alvocidib Drugs 0.000 claims description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 claims description 2
- 229940059720 apra Drugs 0.000 claims description 2
- WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 claims description 2
- ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 claims description 2
- 229960005537 combretastatin A-4 Drugs 0.000 claims description 2
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 claims description 2
- 229940084651 iressa Drugs 0.000 claims description 2
- 229950008959 marimastat Drugs 0.000 claims description 2
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 claims description 2
- 229960002700 octreotide Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229960001639 penicillamine Drugs 0.000 claims description 2
- 229940109328 photofrin Drugs 0.000 claims description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229950001248 squalamine Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 claims description 2
- 229960003433 thalidomide Drugs 0.000 claims description 2
- 229950000578 vatalanib Drugs 0.000 claims description 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 2
- 102000001558 Sialic Acid Binding Ig-like Lectin 1 Human genes 0.000 claims 7
- WORSVFBVUCBRIP-VNQPRFMTSA-N (2r,3s)-n-[(2s)-3,3-dimethyl-1-oxo-1-(pyridin-2-ylamino)butan-2-yl]-n'-hydroxy-3-methoxy-2-(2-methylpropyl)butanediamide Chemical compound ONC(=O)[C@@H](OC)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)(C)C)C(=O)NC1=CC=CC=N1 WORSVFBVUCBRIP-VNQPRFMTSA-N 0.000 claims 1
- GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 claims 1
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 claims 1
- 102400000068 Angiostatin Human genes 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- 108090000644 Angiozyme Proteins 0.000 claims 1
- 102400001047 Endostatin Human genes 0.000 claims 1
- 108010066792 FCE 26644 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 claims 1
- DNUXJWBKTMJNEP-JVSLBXKQSA-N [(2R)-3-[(2S)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(2R,3R,4R,5R)-2-acetamido-4-[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,6-dihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]([C@@H](NC(C)=O)C=O)[C@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@H](O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC DNUXJWBKTMJNEP-JVSLBXKQSA-N 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- SMDHCQAYESWHAE-UHFFFAOYSA-N benfluralin Chemical compound CCCCN(CC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O SMDHCQAYESWHAE-UHFFFAOYSA-N 0.000 claims 1
- 229950009003 cilengitide Drugs 0.000 claims 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 claims 1
- 108700042119 disaccharide tripeptide Proteins 0.000 claims 1
- 239000003596 drug target Substances 0.000 claims 1
- 229940045109 genistein Drugs 0.000 claims 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 1
- 235000006539 genistein Nutrition 0.000 claims 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 1
- 229940094952 green tea extract Drugs 0.000 claims 1
- 235000020688 green tea extract Nutrition 0.000 claims 1
- 230000002607 hemopoietic effect Effects 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims 1
- 229950010895 midostaurin Drugs 0.000 claims 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims 1
- 229950009136 solimastat Drugs 0.000 claims 1
- XUWLTCQVQARIFB-UHFFFAOYSA-J tetrasodium;7-[[4-[[4-[[5-[[5-[(6,8-disulfonatonaphthalen-2-yl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]carbamoylamino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]naphthalene-1,3-disulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=CC(NC(=O)C3=CC(=CN3C)NC(=O)C3=CC(NC(=O)NC4=CN(C)C(C(=O)NC5=CN(C)C(C(=O)NC=6C=C7C(=CC(=CC7=CC=6)S([O-])(=O)=O)S([O-])(=O)=O)=C5)=C4)=CN3C)=CC=C21 XUWLTCQVQARIFB-UHFFFAOYSA-J 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 160
- 239000000047 product Substances 0.000 description 57
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 24
- 238000003757 reverse transcription PCR Methods 0.000 description 23
- 102100032855 Sialoadhesin Human genes 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 206010039491 Sarcoma Diseases 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 102000016911 Deoxyribonucleases Human genes 0.000 description 11
- 108010053770 Deoxyribonucleases Proteins 0.000 description 11
- 238000001574 biopsy Methods 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000012790 confirmation Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000007857 nested PCR Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 102000044465 Galectin-7 Human genes 0.000 description 5
- 101000608772 Homo sapiens Galectin-7 Proteins 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108091033380 Coding strand Proteins 0.000 description 4
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 4
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 4
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 102100033919 Ephrin-A2 Human genes 0.000 description 3
- 108010043942 Ephrin-A2 Proteins 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 102000012803 ephrin Human genes 0.000 description 3
- 108060002566 ephrin Proteins 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000037311 normal skin Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000029792 Desmoplakin Human genes 0.000 description 2
- 108091000074 Desmoplakin Proteins 0.000 description 2
- 241000447394 Desmos Species 0.000 description 2
- 102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 2
- 108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 2
- 102000006397 Ephrin-B1 Human genes 0.000 description 2
- 108010044099 Ephrin-B1 Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102000005871 S100 Calcium Binding Protein A7 Human genes 0.000 description 2
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 description 2
- 102100030995 Sorting nexin-17 Human genes 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229940030793 psoriasin Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 1
- 101150051922 29 gene Proteins 0.000 description 1
- 101150101112 7 gene Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101100108358 Arabidopsis thaliana AGO10 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 1
- 101100313196 Caenorhabditis elegans cct-5 gene Proteins 0.000 description 1
- 101100281516 Caenorhabditis elegans fox-1 gene Proteins 0.000 description 1
- 101100342815 Caenorhabditis elegans lec-1 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 102100035784 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 102000010776 Dual Specificity Phosphatase 3 Human genes 0.000 description 1
- 108010038536 Dual Specificity Phosphatase 3 Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101150083125 GGCX gene Proteins 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 1
- 101000702681 Homo sapiens Sorting nexin-17 Proteins 0.000 description 1
- 101000801114 Homo sapiens Transmembrane protein 134 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 229910020095 MgCl2 a Inorganic materials 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100049053 Mus musculus Vash1 gene Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101150071661 SLC25A20 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108050006340 Sorting nexin-17 Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000008864 Translin Human genes 0.000 description 1
- 108050009189 Translin Proteins 0.000 description 1
- 102100033701 Transmembrane protein 134 Human genes 0.000 description 1
- 101000870331 Vasconcellea cundinamarcensis Cysteine proteinase 2 Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 101150102633 cact gene Proteins 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GKAOGPIIYCISHV-BJUDXGSMSA-N neon-19 Chemical compound [19Ne] GKAOGPIIYCISHV-BJUDXGSMSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 101150109838 tagC gene Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01200228 | 2001-01-23 | ||
| EP01200228.3 | 2001-01-23 | ||
| US32572201P | 2001-09-28 | 2001-09-28 | |
| EP01203703A EP1298221A1 (fr) | 2001-09-28 | 2001-09-28 | Moyens et méthodes pour l'évaluation d'un traitement |
| US60/325,722 | 2001-09-28 | ||
| EP01203703.2 | 2001-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2369183A1 true CA2369183A1 (fr) | 2002-07-23 |
Family
ID=27224257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002369183A Abandoned CA2369183A1 (fr) | 2001-01-23 | 2002-01-23 | Moyens et methodes pour evaluer un traitement |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2004523232A (fr) |
| CA (1) | CA2369183A1 (fr) |
| NZ (2) | NZ537458A (fr) |
| WO (1) | WO2002059558A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4943504B2 (ja) * | 2006-06-02 | 2012-05-30 | ファイザー・プロダクツ・インク | 循環腫瘍細胞アッセイ |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5470824A (en) * | 1991-05-31 | 1995-11-28 | The Regents Of The University Of California | Method to treat Kaposi's sarcoma |
| US5827658A (en) * | 1996-08-09 | 1998-10-27 | The United States Of America As Reprsented By The Department Of Health And Human Services | Isolation of amplified genes via cDNA subtractive hybridization |
| US5858715A (en) * | 1997-01-29 | 1999-01-12 | Incyte Pharmaceuticals, Inc. | Human apoptosis-associated protein |
| US6333152B1 (en) * | 1997-05-21 | 2001-12-25 | The Johnshopkins University | Gene expression profiles in normal and cancer cells |
| WO2000040749A2 (fr) * | 1999-01-06 | 2000-07-13 | Genenews Inc. | Technique de detection de transcrits geniques dans le sang et leur utilisation |
| US6436642B1 (en) * | 1999-04-20 | 2002-08-20 | Curagen Corporation | Method of classifying a thyroid carcinoma using differential gene expression |
| WO2001012172A1 (fr) * | 1999-08-17 | 2001-02-22 | Purdue Research Foundation | Traitement de maladies metastatiques |
-
2002
- 2002-01-23 WO PCT/NL2002/000051 patent/WO2002059558A2/fr active IP Right Grant
- 2002-01-23 NZ NZ537458A patent/NZ537458A/en unknown
- 2002-01-23 JP JP2002559626A patent/JP2004523232A/ja active Pending
- 2002-01-23 CA CA002369183A patent/CA2369183A1/fr not_active Abandoned
- 2002-01-23 NZ NZ526924A patent/NZ526924A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002059558A2 (fr) | 2002-08-01 |
| WO2002059558A3 (fr) | 2003-01-09 |
| WO2002059558A8 (fr) | 2003-11-06 |
| NZ526924A (en) | 2005-09-30 |
| JP2004523232A (ja) | 2004-08-05 |
| NZ537458A (en) | 2007-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dolphin et al. | Differential developmental and tissue‐specific regulation of expression of the genes encoding three members of the flavin‐containing monooxygenase family of man, FMO1, FMO3 and FMO4 | |
| US6057111A (en) | Gene identification method | |
| de Waard et al. | Serial analysis of gene expression to assess the endothelial cell response to an atherogenic stimulus | |
| US20050208486A1 (en) | Brca-1 regulators and methods of use | |
| EP1400596A1 (fr) | Protéine associée au complexe de récepteur d'androgène A | |
| van der Reijden et al. | RT-PCR diagnosis of patients with acute nonlymphocytic leukemia and inv (16)(p13q22) and identification of new alternative splicing in CBFB-MYH11 transcripts | |
| Scurto et al. | A multiplex RT-PCR assay for the detection of chimeric transcripts encoded by the risk-stratifying translocations of pediatric acute lymphoblastic leukemia | |
| JP2003102485A (ja) | 創傷治癒バイオマーカー | |
| US6043340A (en) | Association of kinesin with sensitivity to chemotherapeutic drugs | |
| CA2369183A1 (fr) | Moyens et methodes pour evaluer un traitement | |
| CN108841958A (zh) | 一种检测EGFR基因外显子21L858突变的crRNA及其检测方法 | |
| US20030219772A1 (en) | Means and methods for treatment evaluation | |
| US20030170720A1 (en) | Means and methods for treatment evaluation | |
| AU689840B2 (en) | Association of kinesin with sensitivity to chemotherapeutic drugs | |
| JP2003510028A (ja) | ２５個のヒト分泌タンパク質 | |
| EP1225233A2 (fr) | Moyens et méthodes pour l'évaluation d'un traitement | |
| Arkenbout et al. | Focusing on transcription factor families in atherogenesis: the function of LKLF and TR3 | |
| EP1298221A1 (fr) | Moyens et méthodes pour l'évaluation d'un traitement | |
| AU2002228477A1 (en) | Means and methods for treatment evaluation | |
| EP1424391A1 (fr) | Ensemble de genes participant a l'activation des astrocytes du foie | |
| JP2006509509A (ja) | 脈管形成に関与する遺伝子の同定、および脈管形成障害患者を同定するための脈管形成診断チップの開発 | |
| JP2003527860A (ja) | Ｂｒｃａ−１制御因子およびその使用方法 | |
| Winkles et al. | Identification of FGF-1-inducible genes by differential display | |
| US20040170989A1 (en) | Cellular gene targets for controlling cell growth | |
| Arrigo et al. | Murine embryonic stem cells as a model for stress proteins and apoptosis during differentiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |